Loading…

Myo‐inositol trispyrophosphate‐mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy

Hypoxia and dysfunctional tumor vessels represent a prominent feature of pancreatic cancer, being, at least in part, responsible for chemotherapy resistance and immune suppression in these tumors. We tested whether the increase of oxygen delivery induced in vivo by myo‐inositol trispyrophosphate (IT...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2014-06, Vol.134 (11), p.2572-2582
Main Authors: Raykov, Zahary, Grekova, Svitlana P., Bour, Gaétan, Lehn, Jean Marie, Giese, N.A., Nicolau, Claude, Aprahamian, Marc
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4187-42726deff591fb32f508f018f677c57f32df823e38626513a59d07193884a2773
cites cdi_FETCH-LOGICAL-c4187-42726deff591fb32f508f018f677c57f32df823e38626513a59d07193884a2773
container_end_page 2582
container_issue 11
container_start_page 2572
container_title International journal of cancer
container_volume 134
creator Raykov, Zahary
Grekova, Svitlana P.
Bour, Gaétan
Lehn, Jean Marie
Giese, N.A.
Nicolau, Claude
Aprahamian, Marc
description Hypoxia and dysfunctional tumor vessels represent a prominent feature of pancreatic cancer, being, at least in part, responsible for chemotherapy resistance and immune suppression in these tumors. We tested whether the increase of oxygen delivery induced in vivo by myo‐inositol trispyrophosphate (ITPP) can reverse hypoxia, control tumor growth and improve chemotherapy response. Tumor size, metastatic development (microcomputed tomography scan follow‐up) and the survival of rats and nude or NOD.SCID mice, (bearing syngenic rat and MiaPaCa2‐ or patient‐derived pancreatic tumors), were determined on ITPP and/or gemcitabine treatment. Partial oxygen pressure, expression of angiogenic factors and tumor histology were evaluated. Infiltration and oxidative status of immune cells, as well as chemotherapy penetration in tumors, were determined by fluorescence‐activated cell sorting, fluorometry, nitric oxide release assays, Western blot and confocal microscopy. Weekly intravenous ITPP application resulted in the inhibition of metastasis development and restricted primary tumor growth, showing a superior effect on the rats' survival compared with gemcitabine. ITPP treatment restored tumor normoxia and caused a reduction in hypoxia inducible factor‐1α levels, with subsequent VEGF and Lox downregulation, resulting in improved vessel structure and decreased desmoplasia. The latter effects translated into elevated immune cells influx and improved susceptibility to gemcitabine treatment. Growth of human pancreatic tumor xenografts was strongly inhibited by administration of ITPP. ITPP exploits a two‐stage mechanism causing rapid, early and sustainable late stage normoxia. This is due to the angiogenic factor modulation and vascular normalization, leading to enhanced chemotherapy delivery and synergistic life prolongation, on combination with low doses of gemcitabine. Pancreatic tumors are highly hypoxic, owing to extensive stromal reaction and disturbed angioarchitecture, features that also reduce the uptake of chemotherapeutics and hinder the flow of immune cells into tumors. In this study, treatment with myo‐inositol trispyrophosphate (ITPP), a novel investigational drug (approved for Phase I and II clinical use in humans), was found to reverse hypoxia in rodents with pancreatic tumors. Therapy‐induced reduction of HIF‐1α and VEGF levels resulted in improved vessel structure. ITPP was active especially upon combination with standard gemcitabine chemotherapy. The latter
doi_str_mv 10.1002/ijc.28597
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1507806137</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3248000281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4187-42726deff591fb32f508f018f677c57f32df823e38626513a59d07193884a2773</originalsourceid><addsrcrecordid>eNp1kD1PwzAQhi0EoqUw8AeQJcTAkOKPJHZGVPFRVMQCc-Q6NnWV2sFOgWws7PxGfgkuLTAx3enuuXulB4BDjIYYIXJm5nJIeFawLdDHqGAJIjjbBv24QwnDNO-BvRDmCGGcoXQX9EhKcMoL3gfvt537fPsw1gXTuhq23oSm866ZudDMRKvicqEqE7sKzrrGvRoBvXpWPhhnoXS29a4OsBFWeiVaI6GMrfLQWOhdpWwboLAVVHa2mgf4qBbStGJqrIJKayOF7PbBjhZ1UAebOgAPlxf3o-tkcnc1Hp1PEplizpKUMJJX8SgrsJ5SojPENcJc54zJjGlKKs0JVZTnJM8wFVlRIYYLynkqCGN0AI7XfxvvnpYqtOXcLb2NkWU0wzjKMV1Rp2tKeheCV7psvFkI35UYlSvhZRRefguP7NHm43IaPf2SP4YjcLIBRJCi1j5aMOGP45QWOV1xZ2vuxdSq-z-xHN-M1tFfkASbDQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1507806137</pqid></control><display><type>article</type><title>Myo‐inositol trispyrophosphate‐mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy</title><source>Wiley</source><creator>Raykov, Zahary ; Grekova, Svitlana P. ; Bour, Gaétan ; Lehn, Jean Marie ; Giese, N.A. ; Nicolau, Claude ; Aprahamian, Marc</creator><creatorcontrib>Raykov, Zahary ; Grekova, Svitlana P. ; Bour, Gaétan ; Lehn, Jean Marie ; Giese, N.A. ; Nicolau, Claude ; Aprahamian, Marc</creatorcontrib><description>Hypoxia and dysfunctional tumor vessels represent a prominent feature of pancreatic cancer, being, at least in part, responsible for chemotherapy resistance and immune suppression in these tumors. We tested whether the increase of oxygen delivery induced in vivo by myo‐inositol trispyrophosphate (ITPP) can reverse hypoxia, control tumor growth and improve chemotherapy response. Tumor size, metastatic development (microcomputed tomography scan follow‐up) and the survival of rats and nude or NOD.SCID mice, (bearing syngenic rat and MiaPaCa2‐ or patient‐derived pancreatic tumors), were determined on ITPP and/or gemcitabine treatment. Partial oxygen pressure, expression of angiogenic factors and tumor histology were evaluated. Infiltration and oxidative status of immune cells, as well as chemotherapy penetration in tumors, were determined by fluorescence‐activated cell sorting, fluorometry, nitric oxide release assays, Western blot and confocal microscopy. Weekly intravenous ITPP application resulted in the inhibition of metastasis development and restricted primary tumor growth, showing a superior effect on the rats' survival compared with gemcitabine. ITPP treatment restored tumor normoxia and caused a reduction in hypoxia inducible factor‐1α levels, with subsequent VEGF and Lox downregulation, resulting in improved vessel structure and decreased desmoplasia. The latter effects translated into elevated immune cells influx and improved susceptibility to gemcitabine treatment. Growth of human pancreatic tumor xenografts was strongly inhibited by administration of ITPP. ITPP exploits a two‐stage mechanism causing rapid, early and sustainable late stage normoxia. This is due to the angiogenic factor modulation and vascular normalization, leading to enhanced chemotherapy delivery and synergistic life prolongation, on combination with low doses of gemcitabine. Pancreatic tumors are highly hypoxic, owing to extensive stromal reaction and disturbed angioarchitecture, features that also reduce the uptake of chemotherapeutics and hinder the flow of immune cells into tumors. In this study, treatment with myo‐inositol trispyrophosphate (ITPP), a novel investigational drug (approved for Phase I and II clinical use in humans), was found to reverse hypoxia in rodents with pancreatic tumors. Therapy‐induced reduction of HIF‐1α and VEGF levels resulted in improved vessel structure. ITPP was active especially upon combination with standard gemcitabine chemotherapy. The latter protocol resulted in significant control of metastatic growth, life prolongation, and improved penetration of chemotherapy in tested animals.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.28597</identifier><identifier>PMID: 24214898</identifier><identifier>CODEN: IJCNAW</identifier><language>eng</language><publisher>Hoboken, NJ: Wiley-Blackwell</publisher><subject>Animals ; Antimetabolites, Antineoplastic - therapeutic use ; Apoptosis - drug effects ; Biological and medical sciences ; Blotting, Western ; Cancer ; Cell Proliferation - drug effects ; Deoxycytidine - analogs &amp; derivatives ; Deoxycytidine - therapeutic use ; Drug Synergism ; Fluorescent Antibody Technique ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Hypoxia ; Hypoxia - drug therapy ; Hypoxia - metabolism ; Hypoxia - pathology ; Hypoxia-Inducible Factor 1, alpha Subunit - antagonists &amp; inhibitors ; Hypoxia-Inducible Factor 1, alpha Subunit - metabolism ; Inositol Phosphates - therapeutic use ; ITPP ; Liver Neoplasms - drug therapy ; Liver Neoplasms - metabolism ; Liver Neoplasms - secondary ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical research ; Medical sciences ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Neovascularization, Pathologic ; normoxia ; Oxygen - metabolism ; Pancreas ; Pancreatic cancer ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - metabolism ; Pancreatic Neoplasms - pathology ; Rats ; Rats, Inbred Lew ; Real-Time Polymerase Chain Reaction ; Reverse Transcriptase Polymerase Chain Reaction ; RNA, Messenger - genetics ; Rodents ; Tumor Cells, Cultured ; Tumors</subject><ispartof>International journal of cancer, 2014-06, Vol.134 (11), p.2572-2582</ispartof><rights>2013 UICC</rights><rights>2015 INIST-CNRS</rights><rights>2013 UICC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4187-42726deff591fb32f508f018f677c57f32df823e38626513a59d07193884a2773</citedby><cites>FETCH-LOGICAL-c4187-42726deff591fb32f508f018f677c57f32df823e38626513a59d07193884a2773</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=28339638$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24214898$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raykov, Zahary</creatorcontrib><creatorcontrib>Grekova, Svitlana P.</creatorcontrib><creatorcontrib>Bour, Gaétan</creatorcontrib><creatorcontrib>Lehn, Jean Marie</creatorcontrib><creatorcontrib>Giese, N.A.</creatorcontrib><creatorcontrib>Nicolau, Claude</creatorcontrib><creatorcontrib>Aprahamian, Marc</creatorcontrib><title>Myo‐inositol trispyrophosphate‐mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Hypoxia and dysfunctional tumor vessels represent a prominent feature of pancreatic cancer, being, at least in part, responsible for chemotherapy resistance and immune suppression in these tumors. We tested whether the increase of oxygen delivery induced in vivo by myo‐inositol trispyrophosphate (ITPP) can reverse hypoxia, control tumor growth and improve chemotherapy response. Tumor size, metastatic development (microcomputed tomography scan follow‐up) and the survival of rats and nude or NOD.SCID mice, (bearing syngenic rat and MiaPaCa2‐ or patient‐derived pancreatic tumors), were determined on ITPP and/or gemcitabine treatment. Partial oxygen pressure, expression of angiogenic factors and tumor histology were evaluated. Infiltration and oxidative status of immune cells, as well as chemotherapy penetration in tumors, were determined by fluorescence‐activated cell sorting, fluorometry, nitric oxide release assays, Western blot and confocal microscopy. Weekly intravenous ITPP application resulted in the inhibition of metastasis development and restricted primary tumor growth, showing a superior effect on the rats' survival compared with gemcitabine. ITPP treatment restored tumor normoxia and caused a reduction in hypoxia inducible factor‐1α levels, with subsequent VEGF and Lox downregulation, resulting in improved vessel structure and decreased desmoplasia. The latter effects translated into elevated immune cells influx and improved susceptibility to gemcitabine treatment. Growth of human pancreatic tumor xenografts was strongly inhibited by administration of ITPP. ITPP exploits a two‐stage mechanism causing rapid, early and sustainable late stage normoxia. This is due to the angiogenic factor modulation and vascular normalization, leading to enhanced chemotherapy delivery and synergistic life prolongation, on combination with low doses of gemcitabine. Pancreatic tumors are highly hypoxic, owing to extensive stromal reaction and disturbed angioarchitecture, features that also reduce the uptake of chemotherapeutics and hinder the flow of immune cells into tumors. In this study, treatment with myo‐inositol trispyrophosphate (ITPP), a novel investigational drug (approved for Phase I and II clinical use in humans), was found to reverse hypoxia in rodents with pancreatic tumors. Therapy‐induced reduction of HIF‐1α and VEGF levels resulted in improved vessel structure. ITPP was active especially upon combination with standard gemcitabine chemotherapy. The latter protocol resulted in significant control of metastatic growth, life prolongation, and improved penetration of chemotherapy in tested animals.</description><subject>Animals</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>Blotting, Western</subject><subject>Cancer</subject><subject>Cell Proliferation - drug effects</subject><subject>Deoxycytidine - analogs &amp; derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Drug Synergism</subject><subject>Fluorescent Antibody Technique</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Hypoxia - drug therapy</subject><subject>Hypoxia - metabolism</subject><subject>Hypoxia - pathology</subject><subject>Hypoxia-Inducible Factor 1, alpha Subunit - antagonists &amp; inhibitors</subject><subject>Hypoxia-Inducible Factor 1, alpha Subunit - metabolism</subject><subject>Inositol Phosphates - therapeutic use</subject><subject>ITPP</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - metabolism</subject><subject>Liver Neoplasms - secondary</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred NOD</subject><subject>Mice, SCID</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Neovascularization, Pathologic</subject><subject>normoxia</subject><subject>Oxygen - metabolism</subject><subject>Pancreas</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Rats</subject><subject>Rats, Inbred Lew</subject><subject>Real-Time Polymerase Chain Reaction</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>RNA, Messenger - genetics</subject><subject>Rodents</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp1kD1PwzAQhi0EoqUw8AeQJcTAkOKPJHZGVPFRVMQCc-Q6NnWV2sFOgWws7PxGfgkuLTAx3enuuXulB4BDjIYYIXJm5nJIeFawLdDHqGAJIjjbBv24QwnDNO-BvRDmCGGcoXQX9EhKcMoL3gfvt537fPsw1gXTuhq23oSm866ZudDMRKvicqEqE7sKzrrGvRoBvXpWPhhnoXS29a4OsBFWeiVaI6GMrfLQWOhdpWwboLAVVHa2mgf4qBbStGJqrIJKayOF7PbBjhZ1UAebOgAPlxf3o-tkcnc1Hp1PEplizpKUMJJX8SgrsJ5SojPENcJc54zJjGlKKs0JVZTnJM8wFVlRIYYLynkqCGN0AI7XfxvvnpYqtOXcLb2NkWU0wzjKMV1Rp2tKeheCV7psvFkI35UYlSvhZRRefguP7NHm43IaPf2SP4YjcLIBRJCi1j5aMOGP45QWOV1xZ2vuxdSq-z-xHN-M1tFfkASbDQ</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Raykov, Zahary</creator><creator>Grekova, Svitlana P.</creator><creator>Bour, Gaétan</creator><creator>Lehn, Jean Marie</creator><creator>Giese, N.A.</creator><creator>Nicolau, Claude</creator><creator>Aprahamian, Marc</creator><general>Wiley-Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>20140601</creationdate><title>Myo‐inositol trispyrophosphate‐mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy</title><author>Raykov, Zahary ; Grekova, Svitlana P. ; Bour, Gaétan ; Lehn, Jean Marie ; Giese, N.A. ; Nicolau, Claude ; Aprahamian, Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4187-42726deff591fb32f508f018f677c57f32df823e38626513a59d07193884a2773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>Blotting, Western</topic><topic>Cancer</topic><topic>Cell Proliferation - drug effects</topic><topic>Deoxycytidine - analogs &amp; derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Drug Synergism</topic><topic>Fluorescent Antibody Technique</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Hypoxia - drug therapy</topic><topic>Hypoxia - metabolism</topic><topic>Hypoxia - pathology</topic><topic>Hypoxia-Inducible Factor 1, alpha Subunit - antagonists &amp; inhibitors</topic><topic>Hypoxia-Inducible Factor 1, alpha Subunit - metabolism</topic><topic>Inositol Phosphates - therapeutic use</topic><topic>ITPP</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - metabolism</topic><topic>Liver Neoplasms - secondary</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred NOD</topic><topic>Mice, SCID</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Neovascularization, Pathologic</topic><topic>normoxia</topic><topic>Oxygen - metabolism</topic><topic>Pancreas</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Rats</topic><topic>Rats, Inbred Lew</topic><topic>Real-Time Polymerase Chain Reaction</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>RNA, Messenger - genetics</topic><topic>Rodents</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raykov, Zahary</creatorcontrib><creatorcontrib>Grekova, Svitlana P.</creatorcontrib><creatorcontrib>Bour, Gaétan</creatorcontrib><creatorcontrib>Lehn, Jean Marie</creatorcontrib><creatorcontrib>Giese, N.A.</creatorcontrib><creatorcontrib>Nicolau, Claude</creatorcontrib><creatorcontrib>Aprahamian, Marc</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raykov, Zahary</au><au>Grekova, Svitlana P.</au><au>Bour, Gaétan</au><au>Lehn, Jean Marie</au><au>Giese, N.A.</au><au>Nicolau, Claude</au><au>Aprahamian, Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Myo‐inositol trispyrophosphate‐mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>134</volume><issue>11</issue><spage>2572</spage><epage>2582</epage><pages>2572-2582</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><coden>IJCNAW</coden><abstract>Hypoxia and dysfunctional tumor vessels represent a prominent feature of pancreatic cancer, being, at least in part, responsible for chemotherapy resistance and immune suppression in these tumors. We tested whether the increase of oxygen delivery induced in vivo by myo‐inositol trispyrophosphate (ITPP) can reverse hypoxia, control tumor growth and improve chemotherapy response. Tumor size, metastatic development (microcomputed tomography scan follow‐up) and the survival of rats and nude or NOD.SCID mice, (bearing syngenic rat and MiaPaCa2‐ or patient‐derived pancreatic tumors), were determined on ITPP and/or gemcitabine treatment. Partial oxygen pressure, expression of angiogenic factors and tumor histology were evaluated. Infiltration and oxidative status of immune cells, as well as chemotherapy penetration in tumors, were determined by fluorescence‐activated cell sorting, fluorometry, nitric oxide release assays, Western blot and confocal microscopy. Weekly intravenous ITPP application resulted in the inhibition of metastasis development and restricted primary tumor growth, showing a superior effect on the rats' survival compared with gemcitabine. ITPP treatment restored tumor normoxia and caused a reduction in hypoxia inducible factor‐1α levels, with subsequent VEGF and Lox downregulation, resulting in improved vessel structure and decreased desmoplasia. The latter effects translated into elevated immune cells influx and improved susceptibility to gemcitabine treatment. Growth of human pancreatic tumor xenografts was strongly inhibited by administration of ITPP. ITPP exploits a two‐stage mechanism causing rapid, early and sustainable late stage normoxia. This is due to the angiogenic factor modulation and vascular normalization, leading to enhanced chemotherapy delivery and synergistic life prolongation, on combination with low doses of gemcitabine. Pancreatic tumors are highly hypoxic, owing to extensive stromal reaction and disturbed angioarchitecture, features that also reduce the uptake of chemotherapeutics and hinder the flow of immune cells into tumors. In this study, treatment with myo‐inositol trispyrophosphate (ITPP), a novel investigational drug (approved for Phase I and II clinical use in humans), was found to reverse hypoxia in rodents with pancreatic tumors. Therapy‐induced reduction of HIF‐1α and VEGF levels resulted in improved vessel structure. ITPP was active especially upon combination with standard gemcitabine chemotherapy. The latter protocol resulted in significant control of metastatic growth, life prolongation, and improved penetration of chemotherapy in tested animals.</abstract><cop>Hoboken, NJ</cop><pub>Wiley-Blackwell</pub><pmid>24214898</pmid><doi>10.1002/ijc.28597</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0020-7136
ispartof International journal of cancer, 2014-06, Vol.134 (11), p.2572-2582
issn 0020-7136
1097-0215
language eng
recordid cdi_proquest_journals_1507806137
source Wiley
subjects Animals
Antimetabolites, Antineoplastic - therapeutic use
Apoptosis - drug effects
Biological and medical sciences
Blotting, Western
Cancer
Cell Proliferation - drug effects
Deoxycytidine - analogs & derivatives
Deoxycytidine - therapeutic use
Drug Synergism
Fluorescent Antibody Technique
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Hypoxia
Hypoxia - drug therapy
Hypoxia - metabolism
Hypoxia - pathology
Hypoxia-Inducible Factor 1, alpha Subunit - antagonists & inhibitors
Hypoxia-Inducible Factor 1, alpha Subunit - metabolism
Inositol Phosphates - therapeutic use
ITPP
Liver Neoplasms - drug therapy
Liver Neoplasms - metabolism
Liver Neoplasms - secondary
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical research
Medical sciences
Mice
Mice, Inbred NOD
Mice, SCID
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Neovascularization, Pathologic
normoxia
Oxygen - metabolism
Pancreas
Pancreatic cancer
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - metabolism
Pancreatic Neoplasms - pathology
Rats
Rats, Inbred Lew
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger - genetics
Rodents
Tumor Cells, Cultured
Tumors
title Myo‐inositol trispyrophosphate‐mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A51%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Myo%E2%80%90inositol%20trispyrophosphate%E2%80%90mediated%20hypoxia%20reversion%20controls%20pancreatic%20cancer%20in%20rodents%20and%20enhances%20gemcitabine%20efficacy&rft.jtitle=International%20journal%20of%20cancer&rft.au=Raykov,%20Zahary&rft.date=2014-06-01&rft.volume=134&rft.issue=11&rft.spage=2572&rft.epage=2582&rft.pages=2572-2582&rft.issn=0020-7136&rft.eissn=1097-0215&rft.coden=IJCNAW&rft_id=info:doi/10.1002/ijc.28597&rft_dat=%3Cproquest_cross%3E3248000281%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4187-42726deff591fb32f508f018f677c57f32df823e38626513a59d07193884a2773%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1507806137&rft_id=info:pmid/24214898&rfr_iscdi=true